| Multiple Sclerosis
Rayos vs Lemtrada
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis.Deep comparison between: Rayos vs Lemtrada with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLemtrada has a higher rate of injection site reactions vs Rayos based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lemtrada but not Rayos, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rayos
Lemtrada
At A Glance
Oral
Daily
Corticosteroid
IV infusion
Annual treatment courses
Anti-CD52 monoclonal antibody
Indications
- Dermatitis, Atopic
- Allergic rhinitis (disorder)
- Serum Sickness
- Dermatitis Herpetiformis
- Contact Dermatitis
- Exfoliative dermatitis
- Mycosis Fungoides
- Pemphigus
- Erythema Multiforme
- Congenital Adrenal Hyperplasia
- Hypercalcemia
- thyroiditis; nonsuppurative
- Adrenal gland hypofunction
- Crohn Disease
- Ulcerative Colitis
- Autoimmune hemolytic anemia
- Anemia, Diamond-Blackfan
- Immune thrombocytopenic purpura
- Pure Red-Cell Aplasia
- Acute leukemia
- Lymphoma, Non-Hodgkin
- Multiple Sclerosis
- Cerebral Edema
- Ophthalmia, Sympathetic
- Uveitis
- Chronic Obstructive Airway Disease
- Aspergillosis, Allergic Bronchopulmonary
- Aspiration pneumonitis
- Asthma
- Tuberculosis
- Extrinsic allergic alveolitis
- Bronchiolitis Obliterans Organizing Pneumonia
- Idiopathic eosinophilic pneumonitis
- Idiopathic Pulmonary Fibrosis
- Pneumonia, Lipid
- Sarcoidosis
- Nephrotic Syndrome
- Primary gout
- Ankylosing spondylitis
- Dermatomyositis
- Polymyalgia Rheumatica
- Arthritis, Psoriatic
- Polychondritis, Relapsing
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Lupus Erythematosus, Systemic
- Vasculitis
- Trichinellosis
- Tuberculosis, Meningeal
- Multiple Sclerosis
Dosing
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Multiple Sclerosis First course: 12 mg/day IV infusion on 5 consecutive days; second course: 12 mg/day on 3 consecutive days 12 months after first course; subsequent courses: 12 mg/day on 3 consecutive days as needed, at least 12 months after the last prior dose. Premedicate with high-dose corticosteroids for the first 3 days of each course; administer antiviral prophylaxis starting on the first day of each course for a minimum of 2 months or until CD4+ count >= 200 cells/microliter.
Contraindications
- Known hypersensitivity to prednisone or any excipient
- Known hypersensitivity or anaphylactic reaction to alemtuzumab or any excipient
- HIV infection
- Active infection
Adverse Reactions
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Most common (>=10%) Rash, headache, pyrexia, nasopharyngitis, nausea, urinary tract infection, fatigue, insomnia, upper respiratory tract infection, herpes viral infection, urticaria, pruritus, thyroid gland disorders, fungal infection, arthralgia, pain in extremity, back pain, diarrhea, sinusitis, oropharyngeal pain, paresthesia, dizziness, abdominal pain, flushing, vomiting
Serious Autoimmunity, infusion reactions, stroke and cervicocephalic arterial dissection, malignancies, immune thrombocytopenia, glomerular nephropathies including anti-GBM disease, thyroid disorders, other autoimmune cytopenias, autoimmune hepatitis, hemophagocytic lymphohistiocytosis, adult onset Still's disease, thrombotic thrombocytopenic purpura, autoimmune encephalitis, acquired hemophilia A, immune-mediated colitis, infections, progressive multifocal leukoencephalopathy, acute acalculous cholecystitis, pneumonitis
Postmarketing Acquired hemophilia A, neutropenia, thrombocytopenia, thrombotic thrombocytopenic purpura, stroke (hemorrhagic and ischemic), cervicocephalic arterial dissection, cholecystitis, immune-mediated colitis, autoimmune hepatitis, viral hepatitis, opportunistic infections, progressive multifocal leukoencephalopathy, vasculitis, Guillain-Barre syndrome, hemophagocytic lymphohistiocytosis, sarcoidosis, adult onset Still's disease, autoimmune encephalitis, myasthenia gravis, Lambert-Eaton myasthenic syndrome, pulmonary alveolar hemorrhage, alopecia
Pharmacology
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Alemtuzumab is a humanized IgG1 kappa monoclonal antibody that binds to CD52, a cell surface antigen on T and B lymphocytes, natural killer cells, monocytes, and macrophages, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism by which this exerts therapeutic effects in MS is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rayos
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
Lemtrada
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Rayos
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lemtrada
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Rayos
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Lemtrada
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Rayos.
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LemtradaView full Lemtrada profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.